Bupivacaine

Evidence Level: L5

Predicted Indications: 4

Bupivacaine

Pharmacist Assessment Report

Bupivacaine: Sodium channel–blocking local anesthetic → acrodermatitis chronica atrophicans

One-Sentence Summary

Bupivacaine is a local anesthetic that blocks sodium channels. The TxGNN model predicts it may be relevant to acrodermatitis chronica atrophicans, with a score of 0.9923. However, no clinical trials and no publications currently support this direction, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	acrodermatitis chronica atrophicans
TxGNN Prediction Score	0.9923
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Bupivacaine is generally known as a local anesthetic that blocks sodium channels in nerve fibres, which stops pain signals from being transmitted.

Acrodermatitis chronica atrophicans is a late-stage skin manifestation of Borrelia infection, and it is treated with antibiotics. Bupivacaine has no antimicrobial activity, so no credible disease-modifying link was identified. The high score (0.9923) appears to reflect the model’s closeness between dermatological terms rather than a biological rationale. At most, bupivacaine could be conceived for symptomatic numbing of painful skin lesions, which would not treat the disease itself.

Other predictions in the same list are also weakly supported. Their scores and mechanistic assessments are likewise without clinical evidence, and they do not change the conclusion for the main prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
27290	Bupicain 5mg Injection	vial of 20 ml Injection	Not recorded
124998	Levo Anawin 0.25% Injection	vial of 10 ml Injection	Not recorded
159193	Numbcaine Heavy 20mg Injection	vial of 4 ml Injection	Not recorded
29364	Bupicain Heavy 80mg Injection	vial of 4 ml Injection	Not recorded
3383	Anawin 0.25% Injection	vial of 20 ml Injection	Not recorded

The list shows five of at least 20 valid single-ingredient licences, and the records may be partial. All are injectable products.

Safety Considerations

Drug Interactions: 56 interactions were identified. Moderate-level interactions include aprepitant and liposomal morphine. Many others, such as proton pump inhibitors (pantoprazole, omeprazole, lansoprazole), corticosteroids (prednisone, hydrocortisone, dexamethasone), and ondansetron, have no severity level assigned.
Bupivacaine is known to be myotoxic at high local concentrations, and systemic local anesthetic toxicity is a concern, particularly in neonates and children. These points are relevant to some of the other predicted conditions.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no supporting trials or publications, and no credible mechanistic link to a late-stage Borrelia skin infection. Evidence is at the model-prediction-only level.

To proceed, the following is needed:

Any study directly examining bupivacaine in acrodermatitis chronica atrophicans
Detailed mechanism of action data
Package insert warnings and contraindications from the India regulatory source
A clear clinical rationale showing a benefit beyond symptomatic pain relief
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.